JP2022531205A5 - - Google Patents

Info

Publication number
JP2022531205A5
JP2022531205A5 JP2021564373A JP2021564373A JP2022531205A5 JP 2022531205 A5 JP2022531205 A5 JP 2022531205A5 JP 2021564373 A JP2021564373 A JP 2021564373A JP 2021564373 A JP2021564373 A JP 2021564373A JP 2022531205 A5 JP2022531205 A5 JP 2022531205A5
Authority
JP
Japan
Prior art keywords
rsv
pharmaceutical composition
monoclonal antibody
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531205A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/030619 external-priority patent/WO2020223435A1/en
Publication of JP2022531205A publication Critical patent/JP2022531205A/ja
Publication of JP2022531205A5 publication Critical patent/JP2022531205A5/ja
Priority to JP2025014950A priority Critical patent/JP2025072444A/ja
Pending legal-status Critical Current

Links

JP2021564373A 2019-04-30 2020-04-30 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物 Pending JP2022531205A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025014950A JP2025072444A (ja) 2019-04-30 2025-01-31 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840701P 2019-04-30 2019-04-30
US62/840,701 2019-04-30
PCT/US2020/030619 WO2020223435A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025014950A Division JP2025072444A (ja) 2019-04-30 2025-01-31 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物

Publications (2)

Publication Number Publication Date
JP2022531205A JP2022531205A (ja) 2022-07-06
JP2022531205A5 true JP2022531205A5 (enExample) 2023-05-11

Family

ID=70779897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564373A Pending JP2022531205A (ja) 2019-04-30 2020-04-30 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物
JP2025014950A Pending JP2025072444A (ja) 2019-04-30 2025-01-31 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025014950A Pending JP2025072444A (ja) 2019-04-30 2025-01-31 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物

Country Status (15)

Country Link
US (3) US12024553B2 (enExample)
EP (1) EP3962940A1 (enExample)
JP (2) JP2022531205A (enExample)
KR (1) KR20220002427A (enExample)
CN (1) CN113825767A (enExample)
AU (1) AU2020265676A1 (enExample)
BR (1) BR112021020846A2 (enExample)
CA (1) CA3138180A1 (enExample)
CO (1) CO2021014370A2 (enExample)
EA (1) EA202192776A1 (enExample)
IL (1) IL287443A (enExample)
MX (1) MX2021013248A (enExample)
SG (1) SG11202111748TA (enExample)
TW (1) TWI861099B (enExample)
WO (1) WO2020223435A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
CA3229901A1 (en) * 2021-09-13 2023-03-16 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CA2900110A1 (en) 2013-02-01 2014-08-07 Medimmune, Llc Respiratory syncytial virus f protein epitopes
FR3008921B1 (fr) 2013-07-23 2015-12-25 Safran Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece
ES2795727T3 (es) 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Similar Documents

Publication Publication Date Title
JP2023517236A5 (enExample)
TWI859164B (zh) 利用抗fcrn抗體治療葛瑞夫茲氏眼病之方法
US20200040073A1 (en) Methods for administering anti-il-5 antibodies
CN115666649B (zh) 一种新型冠状病毒抗体的药物组合物及其用途
JP2021501214A5 (enExample)
JP7309816B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2023528441A5 (enExample)
JP2022531205A5 (enExample)
JP2023113883A (ja) 小児患者のための生物薬剤組成物及び方法
JP7722991B2 (ja) 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法
JP2003531866A (ja) 抗体を用いた呼吸器疾患の組合せ治療法
JP2022514561A5 (enExample)
JP2025500483A5 (enExample)
JP2023535792A (ja) コロナウイルス治療のための抗ｃｄ３抗体
JP2024177399A (ja) 呼吸器疾患の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体
JP2023523096A5 (enExample)
WO2024182753A2 (en) Methods for treating influenza infections
WO2021005232A1 (en) Intranasal administration of neutralising antiviral antibodies
WO2025242619A1 (en) Treatment for mucus plugging
CN120000779A (zh) 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途
WO2024146630A1 (zh) 一种tslp抗体治疗哮喘的方法
CN121015902A (zh) 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途
TW202340237A (zh) 尼塞韋單抗預防呼吸道融合細胞病毒下呼吸道感染
TW202547886A (zh) 用於治療ｃ１ｓ介導的疾病和病症的組成物、劑量和方法
WO2025214333A1 (zh) 抗tslp抗体治疗与tslp相关的炎症疾病的方法